


Translational Research and Biomedical Manufacturing



The Translational Research Institute (TRI) is a global leader in facilitating the translation of research into real-world healthcare solutions.

The only institute of its kind in Australia, TRI is situated within Brisbane's biomedical knowledge corridor, 15 minutes drive from the International Airport.

Interconnected excellence

TRI offers world-class facilities that integrate research, preclinical, clinical trial, and manufacturing capabilities - creating a unique environment where discovery, innovation, and translation thrive.

TRI is home to more than 1,100 researchers, clinicians, and industry personnel who support the translation of biomedical discoveries from bench to bedside and the development of assets through pre-clinical and clinical trials to successful commercial outcomes.

Home to world-class facilities

TRI offers highly-specialised facilities, equipment, emerging technologies and expertise to advance research across the development pipeline.

TRI has purpose-built clinical trial facilities and offers state of the art Core Facilities which includes:

- Pre-Clinical Imaging Facility (supporting in vivo and ex vivo imaging)
- Flow Cytometry Facility
- Histology
- Microscopy
- Biological Research Facility
- Gnotobiotics
- Human Immune Model Facility (offering the NOD scid gamma (NSG) genetic strain)

Benefits of working in Australia

- Australia has one of the fastest regulatory paths to initiate clinical trials globally, with an IND not required in Australia.
- The Australian Government's R&D Tax Incentive offers substantial financial support for both Australian and international companies conducting R&D activities in Australia.
 - For companies with an annual turnover under AU\$20 million this can potentially translate into a cash refund up to 48.5% on R&D costs in Australia and on R&D costs outside of Australia.
 - For larger companies, this can assist to reduce tax payable in Australia, with the benefit received being a non-refundable tax offset ranging from 8.5% to 16.5% on top of the company tax rate.
- Positioned to support Asia Pacific (APAC) with strong and stable trade relationships with major global markets including US and Europe.

Pioneering the future of biomanufacturing

TRI's cutting-edge translational manufacturing facility, opening in 2026, is set to become Australia's first on demand cGMP cleanroom, advancing the development of RNA-based therapies, cell therapies, biologics, vaccines, and drug-device combination products.



Australia's first on-demand cGMP manufacturing facility - Coming in 2026



The Translational Research Institute's new translational manufacturing facility will offer on-demand cGMP manufacturing for maturing and innovative biotech, pharma and medtech companies.

Designed to meet both international and Australian regulations and standards, the facility will operate in compliance with all relevant cGMP and ISO requirements.

Supporting diverse manufacturing needs

The facility will enable the manufacture of a range of products:

- biologics (both mammalian and microbial)
- pDNA
- RNA-based products (including mRNA-LNP)
- cell therapies (both allogeneic and autologous)
- drug-device combination products
- drug product (including sterile liquid vials)



Indicative floor plan of cGMP cleanrooms Level 4

Empowering tenants

Tenancy offers access to cGMP cleanrooms (Grade B), wet labs (PC2 compliant), dedicated office spaces, enabling companies to conduct their own cGMP manufacturing, on-site Quality Control (QC), and both process and analytical development.

Tenants will benefit from access to cGMP expertise, onsite technical support and training. These resources will enable companies to develop robust manufacturing processes, scale-up and continue ongoing cGMP manufacturing for Phase 1, Phase 2 and Phase 3 clinical trials meeting both international and Australian requirements.

Companies retain full control over manufacturing, scheduling, and pipeline flexibility—while safeguarding their intellectual property.

"We are well advanced on delivering a new chapter of biomedical manufacturing innovation for Australia with global significance. The addition of TM@TRI will transform TRI into one of the largest end-to-end translational research facilities of its kind in Australia."

David Crowley
General Manager - Translational Biomedical Manufacturing

Proudly funded by the Queensland Government and TRI



Find out more and register your interest:



Contact:
Dr Ryan Parlett
Head of Commercial Operations
Translational Research Institute
+61 427 218 840
ryan.parlett@tri.edu.au